Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE +
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
March 31, 2016 01:00 AM

FDA says biosimilar labels should rely on reference drug data

Adam Rubenfire
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    (This story was updated at 11:15 p.m. ET.)

    Biologic manufacturers may not be pleased with the long-awaited biosimilar labeling guidelines released Thursday by the Food and Drug Administration.

    The agency is recommending that labeling for biosimilars use the clinical data gathered by the product the biosimilar is intended to emulate. Regulators would also allow biosimilar labels to state that the product is biosimilar to the reference product but has product-specific modifications.

    Biosimilars are derived from living organisms and therefore may not be identical to brand-name drugs.

    Federal regulators are likely trying to simplify physicians' understanding of the products' efficacy and safety by allowing biosimilars to use the clinical data that supported the reference product's approval. By definition, a biosimilar product has no clinically meaningful difference in terms of safety, purity and potency.

    Although the FDA notes that the labeling does not need to be identical to information based on the reference product, manufacturers of biologics will likely take issue with competitors using their data for a product that is not exactly the same. A spokesman for the Biotechnology Industry Organization, which represents biologics manufacturers and other biotech companies, said the group was currently reviewing the guidance and not yet in a position to comment.

    Siegmund Gutman, chair of the life sciences patent practice at law firm Proskauer, said the FDA's moves in the biosimilar space have been similar to how the agency established regulations for the generic drug market. Generic drugs typically have identical labels to their name-brand counterpart, as required by laws that ensure patient safety.

    “It's not a completely unprecedented issue,” Gutman said. “People may question whether these drugs should be treated differently…but I think it's a similar situation.”

    Courts have found that generic manufacturers can't be found liable for issues in identical labeling used from a reference product, Gutman said. That may be why the FDA did not require labeling to be identical, and there may be room for future legislation regarding that issue for biosimilars, he said.

    “From the FDA standpoint, they want to take this on a case-by-case basis,” Gutman said. “If we decide that a biosimilar product is safe and effective for use in a particular indication, that there shouldn't be (a difference)…that's the point of the FDA approval process.”

    The "appropriate product-specific modifications” on the biosimilar labels can describe differing indications of use and dosing regimens, the FDA notes. But information from the clinical study of a proposed biosimilar should be used only when it informs the safe and effective use of the product by a provider.

    The agency points out that most clinical studies supporting a biosimilar product would demonstrate its biosimilarity rather than its own safety and efficacy. This kind of information isn't likely to be relevant for provider instruction and could cause confusion, regulators say.

    “Due to the potential for differences in clinical study parameters, we think that including comparative clinical data in biosimilar product labeling would be confusing or even potentially misleading to healthcare providers,” Leah Christl, the FDA's associate director for therapeutic biologics, wrote in a blog post. “Ultimately, the comparative data are useful for the FDA to make a decision about biosimilarity, but are not likely to be relevant to a healthcare provider's prescribing considerations.”

    The guidance also explained that the biosimilar's name should be used in labeling information that describes product-specific indications or risks, but the reference product name should be used in sections that include that product's data, which could report adverse reactions found in clinical trials. If the biosimilar has a proprietary name, the agency recommends using it.

    Christl wrote that the agency is reviewing comments received on its draft guidance on nonproperiatary naming of biosimilar products. In August, the FDA proposed adding a four-letter suffix to the nonproprietary names shared with brand-name biologics. “Biosimilars are relatively new products in FDA's landscape, so there is still a lot of work to do,” she said.

    The newest draft guidance notes that the agency is considering data and information that would support the interchangeability of biosimilars, or the ability of pharmacists to substitute the drugs for brand-name medications without fear of any adverse effects. But the FDA offered no timeline as to when that guidance was coming. Experts have said a determination on interchangeability would offer assurance to insurers and providers, as well as make it easier for a number of yet-to-be-approved biosimilars to hit the market.

    A new analysis by IMS Health released Tuesday showed biosimilars could save the U.S. and Europe's five top markets as much as $110 billion by 2020.

    The products were supposed to spark competition and lower prices of some of the most expensive drugs being sold in the U.S.

    But regulatory hurdles like waiting for guidance from the FDA has prevented many products from gaining approval in the year since the first biosimilar was approved.

    On Thursday, Mizuho Securities analyst Eric Criscuolo said in a research note that the FDA's guidance was positive for industry stakeholders, including Pfenex, Coherus BioSciences, and EPIRUS Biopharma.

    The draft guidance issued Thursday is open for comments for 60 days.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Record 16.3M people enroll in ACA plans
    Record 16.3M people enroll in ACA plans
    367749098.jpg
    US health officials propose annual COVID-19 vaccination for most Americans
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE +
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing